Global Cholesterol-lowering Drugs Market 2017-2027

LONDON, September 4, 2017 /PRNewswire/ --

Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs

The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 181-page report you will receive 89 tables and 107 figures - all unavailable elsewhere.

The 181-page report provides clear detailed insight into the global cholesterol-lowering drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope 

• Global Cholesterol-Lowering Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast from 2017-2027 for the global cholesterol-lowering drugs market by its main segments:
• Statins and Fixed-Dose Combinations
• Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates
• PCSK9 Inhibitors
• Novel Cholesterol-Lowering Drugs

• This report provides revenue forecast from 2017-2027 for the leading drugs under the Statins and Fixed-Dose Combination segment:
• Crestor
• Lipitor
• Livalo
• Lescol/Lescol XL
• Zocor
• Vytorin
• Caduet
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates segment:
• Zetia
• Welchol
• Tricor
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the PCSK9 Inhibitor segment:
• Praluent
• Repatha
• RN316
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the novel cholesterol-lowering drugs segment:
• Juxtapid
• Kynamro
• MK-0859
• Others

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• North America: the US, Canada, Mexico
• South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
• Europe: Germany, France, the UK, Spain, Italy, Rest of Europe
• Asia-Pacific: Japan, China, India, Australia, Thailand, Rest of APAC
• RoW: Middle East, Africa, Other Countries

• Our study provides SWOT and Porter's Five Forces analysis that influence the global cholesterol-lowering drugs market

• Our study discusses the selected leading companies that are the major players in the cholesterol-lowering drugs market:
• AstraZeneca
• Merck & Co
• Pfizer
• Kowa Company
• Daiichi Sankyo
• AbbVie
• Novartis
• Sanofi
• Amgen
• Bristol-Myers Squibb (BMS)

Visiongain's study is intended for anyone requiring commercial analyses for the global cholesterol-lowering drugs market. You find data, trends and predictions.

Buy our report today Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100.

Or click on https://www.visiongain.com/Report/1980/Global-Cholesterol-Lowering-Drugs-Market-2017-2027

List of Companies Mentioned in the Report 

Abbott Laboratories

AbbVie

Accord Healthcare

Aegerion Pharmaceuticals

Alcon

Algorithm SAL

Allergan

Alynlam Pharmaceuticals

Amgen

Apotex

Astellas Pharma

AstraZeneca

Aurobindo

BASF

Bayer

Biomarin Pharmaceuticals

Blu Caribe

Bristol-Myers Squibb

Ciba-Geigy

Daiichi Sankyo

DalCor Pharmaceuticals

Dezima Pharma

Dr Reddy's Laboratories

EGIS Pharmaceuticals

Eli Lilly

Esperion Therapeutics

Eisai

Fresenius Medical Care

Genzyme Corporation

Glenmark

Hetero Laboratories

Impax Laboratories

Intas Pharmaceuticals

Isis Pharmaceuticals

JW Pharmaceutical

Kaneka

Kowa

Kremers Urban Pharmaceuticals

Lek

Lupin

Merck and Co.

Micro Laboratories

Miltenyi-Biotec

Mylan

Novartis

Par Pharmaceuticals

Pfizer

ProEthic Pharmaceuticals

ProNova BioPharma

Ranbaxy

Reckitt Benckiser

Recordati

Regeneron

Roche

Sandoz

Sanofi

Serometrix

Shionogi

Solvay

Sun Pharma

Teva

Torrent Pharmaceuticals

UCB

Valeant

Warner-Lambert

Wockhardt

Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com